

C1 (c) the nanoparticulate drug particles comprise a poorly soluble drug, have an effective average particle size of less than about 1000 nm, and have a surface modifier adsorbed on the surface of the drug.

84. (Once amended) A nanoparticulate aerosol composition for use in a propellant-based pressurized metered-dose inhaler (pMDI) comprising:

- C2
- (a) a nanoparticulate crystalline drug, wherein the drug has a surface modifier adsorbed on the surface thereof, wherein the drug has an effective average particle size of less than about 1000 nm, and wherein the drug has a solubility of less than about 10 mg/mL;
  - (b) essentially each droplet of the aerosol comprises at least one nanoparticulate drug particle, wherein the droplets of the aerosol generated by the pMDI have a diameter of less than or equal to about 100 microns, and
  - (c) a non-aqueous propellant.

85. (Once amended) The aerosol composition of claim 84, wherein the propellant is a non-chlorofluorocarbon (non-CFC) propellant.

Please add the following new claims.

C3 118. (New) The aerosol composition of claim 51, wherein the drug is selected from the group consisting of beclomethasone dipropionate, naproxen, triamcinolone acetonide, budesonide, and an anti-emetic.

119. (New) The aerosol composition of claim 84, wherein the drug is selected from the group consisting of beclomethasone dipropionate, naproxen, triamcinolone acetonide, budesonide, and an anti-emetic.